MDXH MDxHealth SA Expected net earnings per share growth this year

MDxHealth SA (MDXH) focuses on urological molecular diagnostics, which, supported by insurance reimbursements, provides the business with exceptional macro-resilience to crises. The annual EPS variation demonstrates profit dynamics, where the value 24.50 represents the current figure. High barriers to entry are created by DNA analysis method patents and strict compliance with medical protocols.

MDxHealth, Inc. (MDXH): Earnings growth in current year from 07/04/2022 to 11/13/2026

Financial and market metric breakdowns for MDxHealth SA (MDXH)

- current quotes and average value forecast:

Market Chart MDxHealth S.A.|MDXH - Price Target Chart

- market capitalization data:

Market Capitalization MDxHealth, Inc.|MDXH - Total Company Value

- shareholders' equity book value data:

Accounting Value per Share MDxHealth SA|MDXH - Book Capitalization|Capitalization to Book Value Ratio mdxhealth.com|MDXH - Cumulative Company Assets

- debt and liquidity details:

- net income and valuation ratios data:

MDXH - Net Income|Future Net Profit MDxHealth SA|MDXH - P/E Multiple|Future Price to Earnings Multiple MDxHealth, Inc.|MDXH - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation MDxHealth, Inc.|MDXH - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters MDxHealth SA|MDXH - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth mdxhealth.com|MDXH - Earnings per share growth in current year|Expected earnings per share growth for next year MDxHealth SA

Fundamental valuation:MDXH MDxHealth S.A.

This metric measures the year-over-year growth rate of net earnings per common share, allowing investors to assess the efficiency of resource capitalization and the actual trajectory of business profitability. By analyzing the annual EPS growth rate, one can see how the implementation of robotic molecular diagnostic systems by MDxHealth SA (MDXH) reduces manual labor costs, directly converting technological automation into financial results.

Direct competitors